Blog
SARS-CoV-2 Delta Variant and Its Effect on Current Prevention and Treatment Strategies
The SARS-CoV-2 Delta variant (B.1.617.2) that first emerged in India is now the most prevalent Variant of Concern (VOC) in the United Kingdom1 and has
Emergency Use Authorization for Lower Dose Intravenous and Subcutaneous Casirivimab Plus Imdevimab
On June 4, 2021, the dose of casirivimab and imdevimab monoclonal antibody cocktail authorized by the Food and Drug Administration (FDA) was lowered from 2400
New COVID-19 Monoclonal Antibody Granted Emergency Use Authorization
On May 26, 2021, a new COVID-19 monoclonal antibody therapy—sotrovimab (previously VIR-7831)— was added to the list of infusion therapies authorized by the Food and
Research Aimed at Understanding Long COVID
Infection with severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, can leave persistent and prolonged effects in multiple organ systems, causing breathing problems, fatigue, joint
Therapies For COVID-19 Prevention
Other than vaccines, there are currently no therapies approved or authorized for emergency use for prevention of COVID-19. At the beginning of the pandemic, there
COVID-19 Monoclonal Antibodies and Effectiveness Against Variants
The Centers for Disease Control and Prevention (CDC) report that the COVID-19 variant first identified in the U.K.—B.1.1.7—is the most common cause of new infection